Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Lung03: rilvegostomig plus platinum-pemetrexed chemotherapy versus pembrolizumab plus platinum-pemetrexed chemotherapy in first-line PD-L1-positive non-squamous NSCLC
2024-515008-38-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of rilvegostomig in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Overall survival and Progression-free survival. Planned start Feb 2025; status: authorised.
02
Drugs
rilvegostomig
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2024-515008-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515008-38-00.